CLSD · Clearside Biomedical, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Price · CLSD
Income Statement
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $201.0K | $492.0K | $2.33M | - | $1.04M | $90.0K | $230.0K | - | $859.0K | $1.02M |
| Cost of Revenue | $0 | $0 | $0 | - | $0 | $0 | - | - | $0 | $213.0K |
| Gross Profit | $201.0K | $492.0K | $2.33M | - | $1.04M | $90.0K | - | - | $859.0K | $805.0K |
| R&D | $2.93M | $1.58M | $4.46M | - | $4.13M | $4.60M | $5.62M | - | $5.13M | $4.95M |
| SG&A | $4.31M | $2.48M | $2.82M | - | $2.84M | $3.08M | $2.82M | - | $2.64M | $3.13M |
| Total Operating Expenses | $7.24M | $4.06M | $8.44M | - | $7.91M | $8.29M | $8.44M | - | $7.91M | $8.29M |
| D&A | - | - | $85.0K | - | - | - | $28.0K | - | - | - |
| Operating Income | ($7.04M) | ($3.57M) | ($5.21M) | - | ($5.93M) | ($7.59M) | ($8.21M) | - | ($7.05M) | ($7.27M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | - | - | - | - | - | - | - |
| Net Income | ($5.97M) | ($4.50M) | ($8.22M) | - | ($7.69M) | ($7.59M) | ($11.76M) | - | ($9.27M) | ($9.11M) |
| EPS - Basic | ($1.14) | ($0.90) | ($1.65) | - | ($1.50) | ($1.50) | ($2.55) | - | ($2.25) | ($1.95) |
| EPS - Diluted | ($1.14) | ($0.90) | ($1.65) | - | ($1.50) | ($1.50) | ($2.55) | - | ($2.25) | ($1.95) |
Balance Sheet
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.80M | $9.38M | $13.63M | $20.02M | $13.89M | $18.24M | $35.35M | $28.92M | $28.80M | $35.01M |
| Accounts Receivable | $266.0K | $816.0K | $1.54M | $507.0K | $788.0K | $0 | $0 | $170.0K | $882.0K | $255.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $796.0K | $1.13M | $1.91M | $1.45M | $2.36M | $1.58M | $1.36M | $2.21M | $1.87M | $1.89M |
| Current Assets | $8.25M | $11.79M | $15.96M | $21.27M | $25.11M | $29.77M | $36.12M | $30.12M | $30.82M | $36.11M |
| Total Assets | $11.64M | $15.33M | $19.67M | $25.13M | $29.16M | $33.93M | $40.14M | $34.02M | $34.42M | $39.19M |
| Current Liabilities | $2.77M | $3.05M | $5.01M | $4.79M | $5.59M | $5.87M | $5.95M | $6.81M | $5.83M | $5.27M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $65.59M | $64.07M | $65.58M | $63.98M | $63.95M | $62.22M | $61.95M | $49.93M | $47.27M | $44.16M |
| Stockholders' Equity | ($53.95M) | ($48.73M) | ($45.91M) | ($38.85M) | ($34.79M) | ($28.29M) | ($21.81M) | ($15.91M) | ($12.85M) | ($4.97M) |
| Retained Earnings | ($373.96M) | ($367.99M) | ($363.50M) | ($355.27M) | ($347.97M) | ($340.28M) | ($332.69M) | ($320.92M) | ($316.09M) | ($306.82M) |
Cash Flow
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($5.83M) | - | - | - | ($7.85M) | - | - | - |
| Investing Cash Flow | - | - | ($9.0K) | - | - | - | ($57.0K) | - | - | - |
| Financing Cash Flow | - | - | ($553.0K) | - | - | - | $14.34M | - | - | - |
| CapEx | - | - | $9.0K | - | - | - | $57.0K | - | - | - |
| Free Cash Flow | - | - | ($5.84M) | - | - | - | ($7.91M) | - | - | - |
Ratios
| Metric | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 100.0% | 100.0% | 100.0% | - | 100.0% | 100.0% | - | - | 100.0% | 79.1% |
| Operating margin | -3502.5% | -725.2% | -223.4% | - | -571.7% | -8433.3% | -3569.1% | - | -821.2% | -714.1% |
| EBITDA margin | - | - | -219.7% | - | - | - | -3557.0% | - | - | - |
| Net margin | -2971.1% | -913.6% | -352.9% | - | -740.7% | -8437.8% | -5114.3% | - | -1078.8% | -894.5% |
| Free cash flow margin | - | - | -250.6% | - | - | - | -3438.3% | - | - | - |
| FCF / Net income | - | - | 0.71 | - | - | - | 0.67 | - | - | - |
| R&D / Revenue | 1459.2% | 322.0% | 191.5% | - | 397.7% | 5114.4% | 2441.3% | - | 597.7% | 486.1% |
| SG&A / Revenue | 2143.3% | 503.3% | 121.2% | - | 274.0% | 3418.9% | 1227.8% | - | 307.0% | 307.2% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -51.3% | -29.3% | -41.8% | - | -26.4% | -22.4% | -29.3% | - | -26.9% | -23.2% |
| Return on equity | 11.1% | 9.2% | 17.9% | - | 22.1% | 26.8% | 53.9% | - | 72.1% | 183.1% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.98 | 3.87 | 3.19 | 4.44 | 4.49 | 5.07 | 6.07 | 4.42 | 5.28 | 6.85 |
| Quick ratio | 2.98 | 3.87 | 3.19 | 4.44 | 4.49 | 5.07 | 6.07 | 4.42 | 5.28 | 6.85 |
| Cash ratio | 2.46 | 3.08 | 2.72 | 4.18 | 2.48 | 3.10 | 5.94 | 4.24 | 4.94 | 6.64 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -0.22 | -0.31 | -0.43 | -0.65 | -0.84 | -1.20 | -1.84 | -2.14 | -2.68 | -7.88 |
| Liabilities / Assets | 5.63 | 4.18 | 3.33 | 2.55 | 2.19 | 1.83 | 1.54 | 1.47 | 1.37 | 1.13 |
| Efficiency | ||||||||||
| Asset turnover | 0.02 | 0.03 | 0.12 | - | 0.04 | 0.00 | 0.01 | - | 0.02 | 0.03 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 483d | 605d | 241d | - | 277d | 0d | 0d | - | 375d | 91d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | 3232d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -80.6% | 446.7% | 913.0% | - | 20.8% | -91.2% | 5650.0% | - | 222.9% | 165.1% |
| Revenue CAGR (3y) | -8.9% | 8.6% | 88.7% | - | -30.4% | -51.3% | 89.1% | - | -37.0% | 42.2% |
| Revenue CAGR (5y) | -43.3% | 6.8% | -10.7% | - | 49.1% | 14.9% | 38.6% | - | 40.8% | 50.9% |
| Gross profit growth (YoY) | -80.6% | 446.7% | - | - | 20.8% | -88.8% | - | - | - | - |
| Operating income growth (YoY) | -18.6% | 53.0% | 36.6% | - | 15.9% | -4.4% | -7.9% | - | -4.9% | 7.2% |
| Net income growth (YoY) | 22.3% | 40.8% | 30.1% | - | 17.0% | 16.6% | -26.8% | - | -18.4% | -16.5% |
| EPS growth (YoY) | 24.0% | 40.0% | 35.3% | - | 33.3% | 23.1% | -1861.5% | - | -2712.5% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 26.2% | - | - | - | -9.6% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -55.1% | -72.3% | -110.5% | -144.2% | -170.8% | -468.8% | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Product / service
$3.30M totalLicense$1.70M · 51.5%
Training Materials And Clinical Supplies$900.0K · 27.3%
Product And Service Other$700.0K · 21.2%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Clearside Biomedical against the 5 most active filers in the same SIC group.